Friday, July 10, 2026

pharma · Mantle Cell Lymphoma · Colon cancer

Telethon Foundation

Fondazione Telethon ETS is a pharma organization headquartered in EU. Primary therapeutic focus areas include Mantle Cell Lymphoma, Colon cancer, colorectal cancer, NSCLC non-small cell lung cancer, Follicular lymphoma.

roma, IT HQ
1990 Founded
343 Employees
EMA registrant Type
Company details
Status
Public
HQ
roma, IT
Founded
1990
Employees
343
Programs
162
Drugs
285
Patents
0
Clinical program

PTG-CARCIK-CD19

Phase 2 · small molecule · B-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

PTG-CARCIK-CD19 for B-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

← All Fondazione Telethon ETS projects Phase 2 small molecule active

Internal code FT04CARCIK

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Fondazione Telethon ETS
Phase
Phase 2
Modality
small_molecule
Indication
B-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status
active
Trials
1

Clinical trials